{"id":"standard-quadruple-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Optic neuritis"}]},"_chembl":{"chemblId":"CHEMBL261657","moleculeType":"Small molecule","molecularWeight":"405.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Quadruple therapy refers to a fixed combination of four drugs designed to work synergistically against a pathogen. In tuberculosis, this typically includes isoniazid, rifampicin, pyrazinamide, and ethambutol. In H. pylori infection, it may include a proton pump inhibitor, bismuth subsalicylate, and two antibiotics. The multi-drug approach reduces resistance development and improves treatment efficacy.","oneSentence":"Standard quadruple therapy combines four antimicrobial agents to treat infections, typically used in tuberculosis or Helicobacter pylori eradication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:28.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (drug-susceptible)"},{"name":"Helicobacter pylori infection (refractory cases)"}]},"trialDetails":[{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT06943794","phase":"NA","title":"Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":"Gastric (Stomach) Cancer","enrollment":4824},{"nctId":"NCT07334535","phase":"PHASE4","title":"Isa-VRD in TIE HRMM","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-30","conditions":"Multiple Myeloma","enrollment":117},{"nctId":"NCT07104318","phase":"PHASE3","title":"Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Helicobacter Pylori","enrollment":360},{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT05790525","phase":"PHASE4","title":"Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-11-22","conditions":"Helicobacter Pylori","enrollment":200},{"nctId":"NCT06942559","phase":"NA","title":"Brain-Oscillation Synchronized Stimulation of the DMPFC","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2025-01-29","conditions":"Obsessive Compulsive Disorder (OCD), Treatment Resistant Obsessive Compulsive Disorder","enrollment":48},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT05572957","phase":"NA","title":"LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-10-14","conditions":"Non-ischemic Cardiomyopathy, Heart Failure, Left Bundle-Branch Block","enrollment":50},{"nctId":"NCT06082323","phase":"PHASE1","title":"A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers","status":"RECRUITING","sponsor":"Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.","startDate":"2024-06-13","conditions":"Healthy Volunteer, Hidradenitis Suppurativa, Atopic Dermatitis","enrollment":127},{"nctId":"NCT05534750","phase":"PHASE2","title":"Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-20","conditions":"Tuberculosis, Multidrug Resistant Tuberculosis","enrollment":60},{"nctId":"NCT06777732","phase":"EARLY_PHASE1","title":"The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-03","conditions":"Helicobacter Pylori Infection","enrollment":672},{"nctId":"NCT03640312","phase":"PHASE2","title":"Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-08-30","conditions":"Hypertension","enrollment":62},{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404},{"nctId":"NCT05664685","phase":"PHASE4","title":"Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-10-17","conditions":"Helicobacter Pylori Infection","enrollment":127},{"nctId":"NCT06315478","phase":"PHASE4","title":"Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-02-01","conditions":"H.Pylori Infection","enrollment":60},{"nctId":"NCT06275204","phase":"","title":"H. Pylori Screen-and-treat Study in a Population of Young Adults","status":"RECRUITING","sponsor":"University of Latvia","startDate":"2024-03-04","conditions":"Gastric Cancer, H Pylori Infection, H Pylori Eradication","enrollment":6800},{"nctId":"NCT06273280","phase":"NA","title":"Renal-based Optimization of QUADruple Therapy in Patients With Heart Failure With Reduced Ejection Fraction.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2024-02-14","conditions":"Heart Failure, Heart Failure With Reduced Ejection Fraction","enrollment":345},{"nctId":"NCT06143124","phase":"PHASE4","title":"Bismuth Quadruple Therapy Versus Standard Triple Therapy","status":"UNKNOWN","sponsor":"University Medical Centre Ljubljana","startDate":"2022-03-03","conditions":"Helicobacter Pylori Infection","enrollment":216},{"nctId":"NCT05377203","phase":"PHASE4","title":"Low-dose Quadruple Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2022-07-13","conditions":"Hypertension, Arterial Hypertension","enrollment":90},{"nctId":"NCT05850117","phase":"NA","title":"Efficacies of Tetracycline-levofloxacin, Standard Bismuth, Amoxicillin-levofloxacin Quadruple Therapy for H.p","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2020-02-10","conditions":"Helicobacter Pylori Eradication","enrollment":240},{"nctId":"NCT04660123","phase":"PHASE4","title":"A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-12-20","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":959},{"nctId":"NCT05635942","phase":"PHASE4","title":"Optimized-dose Amoxicillin Versus Standard-dose Amoxicillin for Quadruple Therapy in Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Les Laboratoires des Médicaments Stériles","startDate":"2019-01-29","conditions":"Helicobacter Pylori","enrollment":88},{"nctId":"NCT05189444","phase":"NA","title":"The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2022-03-25","conditions":"Helicobacter Pylori Infection","enrollment":672},{"nctId":"NCT01560572","phase":"PHASE4","title":"Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Renal Insufficiency, Kidney Transplantation","enrollment":305},{"nctId":"NCT03688828","phase":"NA","title":"Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2018-11-11","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT03049995","phase":"","title":"Stress Echo 2020 - The International Stress Echo Study","status":"UNKNOWN","sponsor":"Fatebenefratelli Hospital","startDate":"2016-11","conditions":"Coronary Artery Disease, Heart Failure, Hypertrophic Cardiomyopathy","enrollment":300},{"nctId":"NCT04652284","phase":"PHASE3","title":"Effectiveness of Rifabutin for Treatment of Helicobacter Pylori","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2021-05-01","conditions":"Helicobacter Infections, Resistance Bacterial, Gastritis H Pylori","enrollment":300},{"nctId":"NCT04617613","phase":"PHASE4","title":"Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2016-09","conditions":"Helicobacter Pylori Infection","enrollment":603},{"nctId":"NCT02557932","phase":"PHASE3","title":"Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2015-09","conditions":"Helicobacter Pylori Infection, Family History of Stomach Cancer","enrollment":352},{"nctId":"NCT04034641","phase":"PHASE4","title":"Effect of Probiotics on Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Hangzhou Grand Biologic Pharmaceutical, Inc.","startDate":"2019-06-17","conditions":"Helicobacter Pylori Eradication","enrollment":238},{"nctId":"NCT01967329","phase":"PHASE4","title":"CANHelp Working Group Treatment Trials","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2008-11","conditions":"Helicobacter Pylori Infection","enrollment":338},{"nctId":"NCT03968302","phase":"PHASE2","title":"ADDITION OF BISMUTH TO THE STANDARD TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION","status":"COMPLETED","sponsor":"Ziauddin University","startDate":"2018-06-01","conditions":"Helicobacter Pylori Infection","enrollment":196},{"nctId":"NCT01404325","phase":"PHASE3","title":"Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-02-01","conditions":"Lung Transplantation","enrollment":130},{"nctId":"NCT02621359","phase":"PHASE3","title":"A Two Week Nitazoxanidebased Quadruple Regimen","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2015-01","conditions":"Dyspepsia","enrollment":100},{"nctId":"NCT01769365","phase":"PHASE4","title":"Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2010-07","conditions":"Helicobacter Pylori Infection","enrollment":307},{"nctId":"NCT01481844","phase":"PHASE3","title":"Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection","status":"COMPLETED","sponsor":"Soroka University Medical Center","startDate":"2011-11","conditions":"Optimization of Second Line Treatment Protocol for H Pylori Eradication","enrollment":101},{"nctId":"NCT01725542","phase":"PHASE2","title":"Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-12","conditions":"HCV-HIV Co-Infection","enrollment":75},{"nctId":"NCT01219764","phase":"PHASE4","title":"A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2010-10","conditions":"Helicobacter Infections","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Qs-14"],"phase":"marketed","status":"active","brandName":"standard quadruple therapy","genericName":"standard quadruple therapy","companyName":"Les Laboratoires des Médicaments Stériles","companyId":"les-laboratoires-des-m-dicaments-st-riles","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Standard quadruple therapy is a treatment modality that involves the use of small molecule drugs. It has been studied in various clinical trials for conditions such as Tuberculosis, Multidrug Resistant Tuberculosis, Helicobacter Pylori, and Multiple Myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}